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The development of anemia during critical illness is hemato-
logically similar to the anemia of chronic disease/inflammation
(ACD), except that the onset is generally acute. Blunting of
endogenous erythropoietin production, mediated through the
action of inflammatory cytokines, is thought to be the most
important cause of this common syndrome [1]. Because low
serum iron and elevated serum ferritin levels are also clinical
features of ACD, investigators once believed that altered iron
metabolism was responsible for this condition. This early
hypothesis has merit because iron utilization plays a key role
in anemia and can affect the response to endogenous or
exogenously administered erythropoietin [2]. Nutritional defi-
ciencies (folic acid, vitamin B12, and iron) can possibly con-
tribute to the etiology of early anemia in the intensive care unit
(ICU). In a study conducted by Rodriguez and colleagues [3],
13% of critically ill patients were identified as having poten-
tially correctable nutritional abnormalities, with 9% having lab-
oratory values consistent with iron deficiency (i.e. iron/total
iron binding capacity <15%, with a ferritin level <100 ng/ml).
The relevant iron parameters that characterize anemia in
chronic disease or critical illness, as compared with those in
iron deficiency anemia and normal individuals, are summa-
rized in Table 1. In ACD-type disorders, absorption of iron is
actually stimulated and there are adequate stores of iron in
the bone marrow. Stored iron may not be effectively utilized,
however. Release of iron from macrophages in the reticulo-
endothelial system is defective, ferritin concentrations are
increased, and serum transferrin levels are normal, rather than
elevated [4]. This ‘functional iron deficiency’, when diagnosed
by cytometry, is present in 35% of patients on admission to
the ICU [5]. Disturbed iron metabolism from enhanced
immune activation has also been documented in surgical ICU
patients [6] and in patients with multiple organ dysfunction
syndrome [7].
Regardless of whether iron supply is limited as a result of
nutritional or functional factors, when the iron available to
developing erythroblasts is insufficient to meet the demands
of heme synthesis, maturing red cells may contain suboptimal
hemoglobin [8]. To prevent the synthesis of hypochromic red
cells, administration of iron in conjunction with erythropoietin
therapy should be considered in the critically ill patient, but
when, how much, and by what route should iron be given?
Review
Iron supplementation in the intensive care unit: when, how much,
and by what route?
Marc Lapointe
Associate Professor, Medical University of South Carolina, College of Pharmacy, Charleston, South Carolina, USA
Correspondence: Marc Lapointe, lapointm@musc.edu
Published online: 14 June 2004 Critical Care 2004, 8(Suppl 2):S37-S41 (DOI 10.1186/cc2825)
This article is online at http://ccforum.com/content/8/S2/S37
© 2004 BioMed Central Ltd
Abstract
Derangements of iron metabolism may be present in critically ill patients who develop anemia during a
stay in the intensive care unit. Iron supplementation may be appropriate, especially if an underlying
nutritional disorder is present. It may be even more critical to replace iron when erythropoietin therapy
is used because of the consumption of iron stores that occurs during heme synthesis. Iron therapy is
not without risks, and controversy persists regarding the potential for iron overload and infections.
Clinical trials that define the optimal dose, route, and timing of iron administration in critically ill patients
are lacking. However, studies of iron supplementation in chronic kidney disease, pregnancy, and
anemia of prematurity may provide some guidance about approaches to treatment. Clinical evidence
and limitations that can assist clinicians in managing iron therapy in the intensive care unit are
presented.
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In a recent review of best practice and research in clinical
hematology [8], it was noted that iron uptake into developing
erythroblasts begins at an early stage and is completed
before late erythroblastosis. Precisely when to administer iron
with erythropoietin therapy has not been systematically inves-
tigated. In a study examining health-related quality of life in
rheumatoid arthritis patients receiving treatment with erythro-
poietin, all 28 patients who completed the study responded
to treatment with erythropoietin [9]. However, 82% devel-
oped functional iron deficiency and were well supported with
a mean absolute dose of 710 ± 560 mg intravenous iron
sucrose. In that 12-week study, iron support was not initiated
until the deficiency was noted (after a mean of 4.5 weeks of
treatment). In other small studies conducted in elderly or criti-
cally ill patients, iron support was initiated concurrently with
erythropoietin therapy [10]. Of note, daily intravenous iron
therapy alone or in combination with folic acid did not result
in a significant increase in reticulocyte count among critically
ill patients. The timing of iron administration with erythropoi-
etin clearly warrants further study in larger populations.
Administration of iron in critically ill patients is regarded by
some as undesirable because free iron may promote bacterial
growth and have detrimental effects in patients who are
immunosuppressed or susceptible to infection and sepsis
[11,12]. Iron overload is most commonly associated with
chronic transfusions in patients with refractory anemia [4]
because there is no physiological mechanism to excrete iron;
chelation therapy is generally required to remove it. This con-
stitutes an important reason for careful consideration of iron
dosing and route of administration in the critically ill patient.
When given by the parenteral route, iron has been implicated
in increased susceptibility to bacterial infection [11–14]. This
effect is believed to be related to the influence of iron on the
immune system [15]. The cytokine-mediated defect in iron
release from macrophages in humans is said to have evolved
as a primitive mechanism of defense against microbial
pathogens to limit their access to iron [12]. Studies on the
effects of iron on host defense suggest that increased iron
availability, seen with increased transferrin saturation, leads to
less efficient bacterial killing of various pathogens by plasma
[16]. Elevated serum ferritin level is a risk factor for bacterial
infection in hemodialysis patients [17]. This finding was cor-
roborated by Hoen and colleagues at serum ferritin levels
greater than 500 ng/ml [18], but this was later refuted when
they found no association between serum ferritin and infec-
tion in a large prospective trial [19]. In these studies it is not
clear whether high ferritin levels are associated with iron over-
load or an acute phase reaction, or both. In light of this rather
limited evidence, some advocate that these observations
should not limit iron utilization in patients with chronic kidney
disease (CKD) [20]. Additional studies in critically ill patients
are needed to determine whether there is a clinically relevant
link between infection, septicemia, and iron availability.
Studies of iron supplementation are plentiful in the CKD liter-
ature, in pregnancy, and in the pediatric setting. However,
even in the well studied CKD population, the dosing, route, and
frequency of iron administration are controversial [21–23].
Concomitant use of intravenous iron was deemed superior to
oral iron in patients with chronic renal failure treated with ery-
thropoietin [24]. Total dose infusion therapy versus low dose
intravenous iron replacement were equally effective in
hemodialysis patients receiving erythropoietin therapy [25]. In
pregnancy, the intravenous route of iron administration was
similar to the oral route in terms of measured hemoglobin
increases and toxicity, but intravenous iron increased ferritin
concentrations significantly more than did oral iron [26].
Studies in premature infants have attempted to address the
dosage and timing of iron supplementation. In neonates with
anemia of prematurity, high dose iron (16 mg/kg per day) was
no more effective than low dose (8 mg/kg per day) during ery-
thropoietin therapy [27]. Early iron supplementation in infants
Table 1
Iron parameters characteristic of anemia in chronic disease or critical illness
Parameter (units) ACD Iron deficiency Normal
Serum ferritin (µg/l) >50 <50 15–300
Serum iron (µg/dl) <30 <30 50–150
TIBC (µmol/l) Normal Elevated 47–70
% Saturation >20% <15% 16–40%
RBC zinc protoporphyrin (µg/dl) <1.24 >1.24 <70
Erythropoietin level (mU/ml) Normal (inappropriately low) Elevated 4–28
STfR (mg/l) Normal Elevated 2.8–8.5
TfR-F index Low (<1) High (>4) 1–4
ACD, anemia of chronic disease/inflammation; % saturation = (iron/total iron binding capacity) × 100; STfR, serum transferrin receptor; TfR-F
index, sTfR/ferritin. Values derived from Rodriguez and coworkers [3], Hudson and Comstock [22], Miller and coworkers [49], and Punnonen and
coworkers [50].S39
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was safe and prevented red blood cell transfusions as com-
pared with late iron supplementation [28]; no erythropoietin
was given in that study. Because there is substantial need for
iron in erythropoietin-stimulated erythroid progenitors, Tarng
and colleagues [29] recommended maintenance of serum
ferritin and transferrin saturation levels over 300 ng/ml and
30%, respectively. They also asserted that, in uremic patients,
oral iron is unlikely to keep pace with iron demand, rendering
the response to erythropoietin suboptimal. Thus, intravenous
iron therapy is believed to be the most appropriate choice,
leading to reductions in erythropoietin dosage and costs
[29].
Although oral supplements are usually the first line of treat-
ment because of cost and convenience, oral iron may be
poorly absorbed, associated with increased gastrointestinal
distress, and may not maintain iron stores in critically ill
patients receiving erythropoietic therapy. Studies designed to
examine the optimal dose and route of iron supplementation
in critically ill patients are lacking. In otherwise healthy adults
treated with erythropoietin before elective surgery [30], intra-
venous iron (200 mg iron sucrose twice weekly) was superior
to daily oral iron (160 mg iron sulfate). Parenteral iron formu-
lations are summarized in Table 2. Pain and discoloration at
the injection site, as well as reports of sarcoma at the site of
injection of iron dextran, have discouraged administration of
iron by the intramuscular route. Thus, parenteral iron is now
only given by intravenous infusion. Iron dextran has also been
associated with important incidents of anaphylactic reaction;
however, the newest formulations are considered safer
[22,31]. According to Zager and colleagues [32], parenteral
iron formulations are highly potent pro-oxidants that can
induce tubular and endothelial cell death. In in vitro animal
studies, each formulation demonstrated a markedly different
toxicity profile, with iron sucrose being the most toxic, fol-
lowed by iron gluconate, then iron dextran. Correct timing of
infusion and dose are important to avoiding oversaturation of
physiologic transport mechanisms [33]. Iron administered via
total parenteral nutrition (TPN) solutions has been advocated
in some publications [34]. However, product literature states
that iron formulations should not be mixed with other medica-
tions or in TPN. The administration of iron through TPN
should not be regarded as a first-line option in critically ill
patients until safety, physical compatibility, and efficacy data
become available in the literature [35].
How effective is iron alone in the treatment of anemia or ACD
type disorders? With regard to reducing the need for transfu-
sions, iron has not proven very effective in improving the
capacity for autologous blood donation or in reducing transfu-
sion requirements [10,13,36,37]. Iron was helpful in reducing
erythropoietin requirements for the maintenance of hemoglo-
bin in end-stage renal disease patients on hemodialysis, but a
similar study has not been done in ICU patients [38]. After
1 month of treatment, intravenous iron alone was sufficient to
increase hematocrit in patients with CKD, but the response
was less than that noted in the group administered erythro-
poietin plus iron [39]. In orthopedic surgery patients, those
treated with iron alone did not experience a significant
increase in erythropoietic variables over baseline values, and
the effects of erythropoietin were seen irrespective of the
route (oral or intravenous) of iron administration [40]. Two
studies of erythropoietin in the critically ill were conducted
[36,37] in which patients were treated with iron therapy, but
neither of these two studies addressed the preferred route of
iron administration. Oral iron (at least 150 mg/day elemental
iron) or parenteral iron (if unable to take oral formulation or
inadequate response to iron therapy defined by transferrin
saturation <20% and serum ferritin <100 ng/ml) were admin-
istered to all patients starting on study day 1 for 2–4 weeks.
The question has been raised as to whether iron therapy is
really needed as an adjuvant to erythropoietin therapy. Iron
supplementation was found unnecessary in one small, limited
Table 2
Parenteral iron formulations
Preparation Tradename(s) Dose Comments
Iron dextran InFed® 250–500 mg [51] Requires test dose (25 mg) 1 hour before starting therapy
Dexferrum® Replacement iron = 0.3 ×  Large single doses (100–500 mg) are appropriate
weight (lb) × (100 – [Hb ×  Available in small single doses (50 or 100 mg in 1 or 2 ml)
100/14.8]) [35] May cause anaphylaxis
Sodium ferric gluconate Ferrlecit® High dose used in patients  No test dose required
with severe chronic renal  Available in single dose (62.5 mg in 5 ml)
insufficiency: 250 mg  May cause flu-like symptoms
intravenously over 14 hours [52]
Low dose in hemodialysis 
patients: 62.5 mg/week [53]
Iron sucrose (also known  Venofer® 100–300 mg [54] No test dose required
as iron saccharate) High dose: 250 mg/month in  Available in single dose (100 mg in 5 ml)
hemodialysis patients [53] May cause hypotension and cramps
Hb, hemoglobin.S40
observational study of critically ill surgical patients undergo-
ing erythropoietin treatment [41], because iron store defi-
ciency was not noted during the course of their ICU stay.
However, the majority of clinical evidence shows that, if prop-
erly balanced, iron therapy can help to optimize erythropoietin
treatment. Furthermore, iron deficiency is also the most
common cause of resistance to erythropoietin treatment in
CKD [42]. Finally, adjuvant therapy, such as ascorbic acid, to
increase oral iron absorption and physiologic utilization has
been used in many clinical CKD settings and must be tested
in critically ill patients [43].
Another clinical concern related to iron supplementation in
the ICU is its risk to affect the physiological redox potential.
Iron is a mineral that is essential to cellular homeostasis, but
an excess of iron can affect physiology and lead to cell injury
[44]. During biologic stress, free radicals are formed. These
radicals can have detrimental effects at different cellular
levels (such as nucleic acid modification) and are involved in
many biologic processes that can damage lipid and protein
membranes [45]. The role of oxidative stress secondary to
iron-derived free radicals and depressed antioxidant reserves
has also been associated with pathologic damage in humans
[46]. Free hydroxyl radical formation is catalyzed by iron via
the Fenton reaction, which involves ferrous iron and peroxide.
Although the clinical significance of this biologic reaction and
the formation of reactive oxygen species is still debated,
stress oxidation is certainly a viable reason to avoid iron over-
load and to monitor iron parameters during iron supplementa-
tion and critical illness [47]. Biologic tissues exposed to
higher concentrations of free iron may be prone to oxidative
damage [48].
In summary, clinicians must first understand that the majority
of the clinical data available are derived from the CKD popu-
lation. The final decision to administer supplemental iron will
depend ultimately on the etiology of anemia in the critically ill
patient. Because iron deficiency is noted in a small subset of
critically ill patients, iron supplementation following identifica-
tion of such patients is appropriate. If anemia is multifactorial,
as is usually the case in a critically ill patient, then iron alone
may not be sufficient to stimulate erythropoiesis but may be
useful as an adjunct with erythropoietin. Although not specifi-
cally evaluated in the critically ill, studies in pregnant females,
neonates, and patients with renal disease suggest that higher
iron doses are not more effective than lower ones. Iron over-
load should be avoided because of its association with
adverse effects. Therefore, until proven otherwise, clinicians
should probably monitor iron parameters on a regular basis if
they elect to administer iron and erythropoietin therapies con-
comitantly. Based on the CKD population, these parameters
may help in optimizing therapy while preventing iron overload.
Specific populations of ICU patients (i.e. those with severe
infection or sepsis) may not benefit from iron therapy because
of possibly increased risk for iron-mediated infection,
although this association is still very controversial and is not
based on robust clinical evidence. The optimal dose, route,
and timing of iron administration in critically ill patients, espe-
cially when given concurrently with erythropoietin therapy,
remains an open issue that requires further study.
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